1 alpha,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analogue of 1 alpha,25-dihydroxyvitamin D3, inhibits azoxymethane-induced colonic tumorigenesis - PubMed (original) (raw)
. 1995 Jul 15;55(14):3050-4.
Affiliations
- PMID: 7606726
1 alpha,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analogue of 1 alpha,25-dihydroxyvitamin D3, inhibits azoxymethane-induced colonic tumorigenesis
R K Wali et al. Cancer Res. 1995.
Abstract
Vitamin D3 and its metabolites, particularly 1 alpha,25-dihydroxyvitamin D3 (1 alpha, 25(OH)2D3), have received increasing attention as potential anticarcinogens in the prevention of cancers in a number of organs, including the colon. These agents, however, have the potential to induce hypercalcemia, thus limiting their practical use for these purposes. In the present studies it was, therefore, of interest to determine whether dietary supplementation with 1 alpha,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalcifero l (RO24-5531), a recently synthesized apparently noncalcemic analogue of 1 alpha,25(OH)2D3, inhibited colon cancer induced by azoxymethane (AOM). Rats were placed on a standard diet or fed this diet with supplemental RO24-5531 (2.5 nmol/kg feed) before and during (initiation arm), or after AOM or vehicle administration (postinitiation arm). After 34 weeks of study, animals in each group were sacrificed, and their colons were removed and examined macroscopically and microscopically for the presence of tumors. At the time of sacrifice, the animals' serum calcium, phosphorus, 25-hydroxyvitamin D3 and 1 alpha,25(OH)2D3 levels were also analyzed. The results of these studies demonstrated that dietary RO24-5531 supplementation during the initiation arm of these experiments significantly reduced (by 70%) the incidence of AOM-induced colonic tumors compared to rats on the standard diet without RO24-5531. Moreover, this dietary regimen abolished the development of adenocarcinomas in this model. Although there was also a trend for dietary RO24-5531 supplementation during the postinitiation arm of this study to reduce the incidence of colon tumors, this did not reach statistical significance (P > 0.05). In addition, neither dietary RO24-5531 supplementation regimen significantly influenced the animals' rates of growth or their serum levels of calcium, phosphorus, or 25-hydroxyvitamin D3. These studies, therefore, demonstrate for the first time that supplemental dietary RO24-5531 is a chemopreventive agent in the AOM model of experimental colonic carcinogenesis. They also suggest that this agent may ultimately prove useful in clinical colon cancer chemopreventive trials.
Similar articles
- Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid.
Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, Roy H, Khare S, Brasitus TA. Earnest DL, et al. Cancer Res. 1994 Oct 1;54(19):5071-4. Cancer Res. 1994. PMID: 7923119 - 1 alpha,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat.
Anzano MA, Smith JM, Uskoković MR, Peer CW, Mullen LT, Letterio JJ, Welsh MC, Shrader MW, Logsdon DL, Driver CL, et al. Anzano MA, et al. Cancer Res. 1994 Apr 1;54(7):1653-6. Cancer Res. 1994. PMID: 8137276 - Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV. Reddy BS, et al. Cancer Res. 2000 Jan 15;60(2):293-7. Cancer Res. 2000. PMID: 10667579 - Antitumor effect of vitamin B6 and its mechanisms.
Komatsu S, Yanaka N, Matsubara K, Kato N. Komatsu S, et al. Biochim Biophys Acta. 2003 Apr 11;1647(1-2):127-30. doi: 10.1016/s1570-9639(03)00076-1. Biochim Biophys Acta. 2003. PMID: 12686121 Review.
Cited by
- Calcitriol derivatives with two different side-chains at C-20. Part 4: further chain modifications that alter VDR-dependent monocytic differentiation potency in human leukemia cells.
Garay E, Jankowski P, Lizano P, Marczak S, Maehr H, Adorini L, Uskokovic MR, Studzinski GP. Garay E, et al. Bioorg Med Chem. 2007 Jul 1;15(13):4444-55. doi: 10.1016/j.bmc.2007.04.034. Epub 2007 Apr 25. Bioorg Med Chem. 2007. PMID: 17485214 Free PMC article. - Chemoprevention of colorectal cancer.
Langman M, Boyle P. Langman M, et al. Gut. 1998 Oct;43(4):578-85. doi: 10.1136/gut.43.4.578. Gut. 1998. PMID: 9824590 Free PMC article. Review. - Increased dietary vitamin D suppresses MAPK signaling, colitis, and colon cancer.
Meeker S, Seamons A, Paik J, Treuting PM, Brabb T, Grady WM, Maggio-Price L. Meeker S, et al. Cancer Res. 2014 Aug 15;74(16):4398-408. doi: 10.1158/0008-5472.CAN-13-2820. Epub 2014 Jun 17. Cancer Res. 2014. PMID: 24938764 Free PMC article. - Losartan and Vitamin D Inhibit Colonic Tumor Development in a Conditional Apc-Deleted Mouse Model of Sporadic Colon Cancer.
Dougherty U, Mustafi R, Haider HI, Khalil A, Souris JS, Joseph L, Hart J, Konda VJ, Zhang W, Pekow J, Li YC, Bissonnette M. Dougherty U, et al. Cancer Prev Res (Phila). 2019 Jul;12(7):433-448. doi: 10.1158/1940-6207.CAPR-18-0380. Epub 2019 May 14. Cancer Prev Res (Phila). 2019. PMID: 31088824 Free PMC article. - Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines.
Kawa S, Nikaido T, Aoki Y, Zhai Y, Kumagai T, Furihata K, Fujii S, Kiyosawa K. Kawa S, et al. Br J Cancer. 1997;76(7):884-9. doi: 10.1038/bjc.1997.479. Br J Cancer. 1997. PMID: 9328147 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources